Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 18/20 | 0.35 |
| ▸ | PARP2 | Q9UGN5 | 5/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | DHODH | Q02127 | 1/20 | 0.32 |
| ▸ | TNKS | O95271 | 1/20 | 0.31 |
| ▸ | PARP14 | Q460N5 | 1/20 | 0.31 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.31 |
| ▸ | PARP12 | Q9H0J9 | 1/20 | 0.31 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.31 |
| ▸ | PARP4 | Q9UKK3 | 1/20 | 0.31 |
| ▸ | PARP3 | Q9Y6F1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL207342 | 0.83 | PARP1 (0.42) | PARP1PARP2TNKSPARP14PARP10 | |
| SCHEMBL206072 | 0.80 | KDM4E (0.38) | PARP1PARP2KDM4EALDH1A1DHODH | |
| SCHEMBL206166 | 0.78 | PARP1 (0.37) | PARP1PARP2KDM4EALDH1A1TNKS | |
| SCHEMBL204089 | 0.78 | PARP1 (0.41) | PARP1PARP2TNKSPARP14PARP10 | |
| SCHEMBL206773 | 0.78 | PARP1 (0.49) | PARP1PARP2KDM4EALDH1A1DHODH | |
| SCHEMBL203819 | 0.77 | PARP1 (0.40) | PARP1PARP2TNKSPARP14PARP10 | |
| SCHEMBL4194880 | 0.74 | PARP1 (0.61) | PARP1PARP2 | |
| SCHEMBL205983 | 0.73 | PARP1 (0.36) | PARP1PARP2KDM4EALDH1A1DHODH | |
| SCHEMBL205061 | 0.73 | PARP1 (0.44) | PARP1PARP2TNKSPARP14PARP10 | |
| SCHEMBL204714 | 0.73 | PARP1 (0.51) | PARP1PARP2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088760-B2 | Benzoxazole carboxamide inhibitors of poly(ADP-ribose)polymerase (PARP) | BIOMARIN PHARMACEUTICAL INC. (US) | 2012-01-03 | — | — | US | claimed |
| EP-2247600-A2 | BENZOXAZOLE CARBOXAMIDE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | Lead Therapeutics, Inc. (US) | 2010-11-10 | — | — | EP | claimed |
| WO-2009099736-A2 | BENZOXAZOLE CARBOXAMIDE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | LEAD THERAPEUTICS, INC. (US) | 2009-08-13 | — | — | WO | claimed |
| US-20090197863-A1 | BENZOXAZOLE CARBOXAMIDE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | LEAD THERAPEUTICS, INC. (US) | 2009-08-06 | — | — | US | claimed |
| US-8088760-B2 | Benzoxazole carboxamide inhibitors of poly(ADP-ribose)polymerase (PARP) | BIOMARIN PHARMACEUTICAL INC. (US) | 2012-01-03 | — | — | US | disclosed |
| EP-2247600-A2 | BENZOXAZOLE CARBOXAMIDE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | Lead Therapeutics, Inc. (US) | 2010-11-10 | — | — | EP | disclosed |
| WO-2009099736-A2 | BENZOXAZOLE CARBOXAMIDE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | LEAD THERAPEUTICS, INC. (US) | 2009-08-13 | — | — | WO | disclosed |
| US-20090197863-A1 | BENZOXAZOLE CARBOXAMIDE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | LEAD THERAPEUTICS, INC. (US) | 2009-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197863-A1 | BENZOXAZOLE CARBOXAMIDE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | PARP1, PARP2, PARP11 | PARP1 1/4885PARP2 2/4885KDM4E 1650/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.